. Author manuscript; available in PMC: 2009 Jun 8.

Published in final edited form as: Eur J Appl Physiol. 2008 Jul;103(4):421–430. doi: 10.1007/S00421-008-0735-5

Table 3.

Cardiovascular response during exercise with placebo and sildenafil

Exercise

Minutes	3			6			9			12

Condition	Norm	HypPla	HypSild	Norm	HypPla	HypSild	Norm	HypPla	HypSild	Norm	HypPla	HypSild
n	14	14	14	14	14	14	14	14	14	10	10	10
Watts	38 ± 7	38 ± 7	38 ± 7	75 ± 15	75 ± 15	75 ± 15	113 ± 22	113 ± 22	113 ± 22	150 ± 29	150 ± 29	150 ± 29
VO₂ (ml/kg/min)	17 ± 3	16 ± 4	19 ± 5	21 ± 5	20 ± 4	21 ± 5	25 ± 4	23 ± 5	24 ± 3	30 ± 5	24 ± 3^†	27 ± 3^†^*
RVSP (mmHg)										53 ± 14	55 ± 20	57 ± 16
SaO₂ (%)	98.5 ± 0.7	83.5 ± 5.8^†	83.2 ± 3.7^†	97.6 ± 1.6	82.4 ± 4.6^†	83.4 ± 3.6^†	97.9 ± 1.7	80.8 ± 4.0^†	82.4 ± 2.4^†^*	98.2 ± 0.8	81.1 ± 3.9^†	82.2 ± 3.0^†
Q (1/min)	9.0 ± 1.7	9.1 ± 2.1	8.8 ± 1.8	11.0 ± 1.9	10.7 ± 2.4	10.4 ± 1.9	13.1 ± 2.6	12.4 ± 3.8	11.9 ± 2.4	14.5 ± 5.0	14.4 ± 5.0	13.1 ± 2.9
HR (beats/min)	93 ± 17	101 ± 17	103 ± 17	105 ± 18	116 ± 16^†	118 ± 22^†	124 ± 18	137 ± 18^†	138 ± 21^†	141 ± 21	158 ± 17^†	157 ± 21^†
SV (ml/beat)	100 ± 23	91 ± 26	88 ± 30	109 ± 29	89 ± 40	92 ± 23	109 ± 33	89 ± 39	83 ± 36	97 ± 45	92 ± 34	72 ± 40
SBP (mmHg)	121 ± 12	117 ± 14	119 ± 13	132 ± 12	130 ± 16	131 ± 17	143 ± 11	149 ± 21	141 ± 20	157 ± 16	161 ± 23	151 ± 21
DBP (mmHg)	75 ± 11	70 ± 10	59 ± 19^†	73 ± 9	62 ± 8^†	55 ± 18^†	71 ± 8	56 ± 20^†	45 ± 26	66 ± 9	37 ± 30^†	32 ± 30^†
MAP (mmHg)	98 ± 9	94 ± 10	89 ± 14	103 ± 8	96 ± 10^†	93 ± 12	107 ± 8	103 ± 17	93 ± 19^†^*	112 ± 9	92 ± 33^†	86 ± 32^†
BNP (pg/ml)										9.3 ± 8.4	9.2 ± 8.2	9.2 ± 6.8
ET-1 (pg/ml)										0.7 ± 0.2	1.2 ± 0.2^†	1.3 ± 0.2^†

VO₂ oxygen uptake, RVSP right ventricular systolic pressure, SaO₂ oxygen saturation, Q cardiac output, HR heart rate, SV stroke volume, SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial blood pressure, BNP brain-type natriuretic peptide, ET-1 endothelin-1.

^†

P < 0.05 compared to normoxia

P < 0.05 placebo versus sildenafil. Values are mean ± SD